What is the START study?

The START (Synaptic Therapy Alzheimer’s Research Trial) is a Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of an investigational medication, CT1812, in people with early Alzheimer’s disease (AD). Approximately 540 participants will be enrolled in the study across 50-60 study centers. CT1812, or its placebo, will be administered daily in the form of two capsules for 18 months. Other study procedures include blood draws, brain imaging with MRI (magnetic resonance imaging) and PET (positron emission tomography) or LP (lumbar puncture) and questionnaires related to memory and thinking.  

What is the purpose of the START study?

The purpose of the START study is to see if the investigational medication, CT1812, can safely slow memory loss in people who already have a diagnosis of mild AD or mild cognitive impairment (MCI). The study will also investigate if CT1812 can show positive benefits to participants’ overall memory, thinking and function over 18 months.

Eligibility

Men or women between the ages of 50 – 80 years old. They must also have a diagnosis of mild AD dementia or a diagnosis of (MCI) due to AD or have memory concerns noticed by another person. Participants will also need a study partner who can join them for some visits.

If you are interested in learning more about the START study, please contact the Memory and Aging Program Outreach Team at 401-455-6402 or by sending an email to memory@butler.org. Ask for the “START study.”